Halberd Corporation (OTCMKTS: HALB) is up big after the Company reported Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19.
This comes as huge news to Halberd and Arizona State University (ASU) who have been working together to develop Halberd’s Covid-19 treatments based on the Company’s valuable intellectual property portfolio. Previously the group secured $2 million in funding.
Halberd Corporation (OTCMKTS: HALB) is a holding Company and acquisition vehicle for established businesses operating out of Jackson Center, Pennsylvania. The Company has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus’. The issued patents’ extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others.
Halberd has developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.
Halberd Corp has a jv on Covid-19 treatment that starts with Dr. Mitchell Felder’s patented extracorporeal therapy (US Patent 9,216,386 and US Patent 8,758,287) for the safe removal of targeted antigens from the blood and targeted organs. The Company has also secured $2 million in funding for the project. Earlier this year Halberd signed a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.
To Find out the inside Scoop on HALB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Halberd recently obtained exclusive world-wide rights to the provisional patent, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans” by Mitchell S. Felder, MD (U.S. Application # 63080735). Halberd expanded its work with Arizona State University to address three major aspects against the Coronavirus.” Halberd scientists have determined the reason adults are more susceptible to coronavirus may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells. ACE2 (3) is a membrane protein expressed in many organs such as nasal and lung epithelial cells. Traditionally, ACE 2 has a key role in the blood pressure regulatory system. Scientific evidence (4, 5) has shown that Covid-19 virus molecules bind to ACE2 receptors to infect nasal epithelial cells, and thus spread the disease through the respiratory system.
On October 13 Halberd reported Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection. Development continues toward three major potential utilizations of the antibody against the Coronavirus: A Preventative; A Diagnostic, and A Therapeutic Treatment. The Company is currently filing patent applications as well as initiating studies to investigate commercial potential for Halberd’s intellectual property as well as explore other potential applications for Halberd’s patented extracorporeal technology, such as PTSD, Cancer, etc.
William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “We are very excited about our progress to date and plan to issue regular progress reports to keep the public aware of our significant developments.”
— BlueBull (@BlueBullTrading) October 13, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Currently running northbound HALB is an exciting story developing in small caps; the Company just reported Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. This comes as huge news to Halberd and Arizona State University (ASU) who have been working together to develop Halberd’s Covid-19 treatments based on the Company’s valuable intellectual property portfolio. Previously the group secured $2 million in funding. Halberd owns a valuable intellectual property portfolio including the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287. We will be updating HALB as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with HALB.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in HALB either long or short and we have not been compensated for this article.